PARP1 and neoplasm: The results showed that tumor growth was more strongly inhibited following combined administration of PRMT6 and PARP1 inhibitors, compared with either monotreatment (Figure 7L,M and Figure S5A, Supporting Information), indicating a potent synergetic antitumor effect of the inhibitor in breast cancer.